EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Seyed Adel Moallem, Amirhossein Sahebkar

EXCLI Journal · 21.04.2023 · 22 · 403-414

DOI: 10.17179/excli2023-6022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 21.04.2023. Verfasst von Habib Yaribeygi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.

Schlagwörter

Stichwörter der Autor:innen

cirrhosisdiabetes mellitusfibrosishepatocellular carcinomalivernon-alcoholic fatty liver disorderssodium-glucose cotransporter-2 inhibitors

Autor:innen und Institutionen

  • Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
  • Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmacology and Toxicology, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq.
  • Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Zitieren

APA

Yaribeygi, H., Maleki, M., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023). Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI Journal, 22, 403-414. https://doi.org/10.17179/excli2023-6022

Vancouver

Yaribeygi H, Maleki M, Jamialahmadi T, Moallem SA, Sahebkar A. Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI Journal. 2023;22:403-414. doi:10.17179/excli2023-6022

BibTeX
@article{Yaribeygi2023,
  author = {Yaribeygi, Habib and Maleki, Mina and Jamialahmadi, Tannaz and Moallem, Seyed Adel and Sahebkar, Amirhossein},
  title = {Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders},
  journal = {EXCLI Journal},
  year = {2023},
  volume = {22},
  pages = {403--414},
  doi = {10.17179/excli2023-6022}
}
Kostenlos starten →